| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/02/2002 | US20020052367 Pharmaceutical compositions containing carvedilol and hydrochlorothiazide |
| 05/02/2002 | US20020052364 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors |
| 05/02/2002 | US20020052361 Pharmaceutical compositions and method for the treatment of hypertension |
| 05/02/2002 | US20020052356 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 05/02/2002 | US20020052348 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase |
| 05/02/2002 | US20020052347 Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates |
| 05/02/2002 | US20020052346 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/02/2002 | US20020052344 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) |
| 05/02/2002 | US20020052337 Composition and method for inhibiting platelet aggregation |
| 05/02/2002 | US20020052333 Therapeutic use of cis-element decoys in vivo |
| 05/02/2002 | US20020052326 Treating diabetes and related diseases in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. |
| 05/02/2002 | US20020052323 Protease inhibitors, particularly for caspase enzyme; treating arthritis, ALS, MS, and the like. |
| 05/02/2002 | US20020052309 Use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium |
| 05/02/2002 | US20020052033 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 05/02/2002 | US20020052022 Molecular cloning of a chemokine like 7TMR (AXOR87) |
| 05/02/2002 | US20020051984 Nucleotide sequences coding cell proliferation protein; for use in the treatment of cancer, wounds, inflammation, arthritis, psoraisis, vision and cell proliferation defects |
| 05/02/2002 | US20020051810 (a) ferulic acid or ester, and (b) caffeic acid and/or a chlorogenic acid |
| 05/02/2002 | US20020051782 Anti-CCR2 antibodies and methods of use therefor |
| 05/02/2002 | US20020051781 CC-chemokine receptor 2 (CCR2) bound by an immunoglobulin or an antigen-binding fragment |
| 05/02/2002 | US20020051771 Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders |
| 05/02/2002 | US20020051766 Treating an aliquot of patient's blood ex vivo with a stressor selected from temperature above or below body temperature, an electromagnetic emission and an oxidative environment, followed by administering back into patient |
| 05/02/2002 | EP1202065A1 Net, a transcription factor of the TCF family, as regulator of angiogenic expression. |
| 05/02/2002 | EP1201679A2 Angiotensin I-converting enzyme inhibitory substance |
| 05/02/2002 | EP1201664A1 Benzimidazole compounds and drugs containing the same |
| 05/02/2002 | EP1201639A2 Lipoxin compounds and their use in treating cell proliferative disorders |
| 05/02/2002 | EP1201248A2 Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease |
| 05/02/2002 | EP1201240A2 Heterocyclic derivatives useful as pharmaceutical agents |
| 05/02/2002 | EP1201236A1 Medicinal compositions for preventing or treating viral myocarditis |
| 05/02/2002 | EP1201235A1 Neuropathy improvers containing nitrogenous compounds as the active ingredient |
| 05/02/2002 | EP1201137A1 Cysteine/glycine rich peptides |
| 05/02/2002 | EP1200831A1 Modulating binding site on potassium channels used for screening |
| 05/02/2002 | EP1200596A2 Human synthetases |
| 05/02/2002 | EP1200595A2 Myxoma virus genes for immune modulation |
| 05/02/2002 | EP1200593A2 The il-1l1 gene and polypeptide products |
| 05/02/2002 | EP1200587A2 Receptors and associated proteins |
| 05/02/2002 | EP1200586A2 Human nervous system-associated proteins |
| 05/02/2002 | EP1200582A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 05/02/2002 | EP1200560A1 Melanin-concentrating hormone receptor |
| 05/02/2002 | EP1200559A2 Muscle cells and their use in cardiac repair |
| 05/02/2002 | EP1200457A2 Cysteine protease inhibitors |
| 05/02/2002 | EP1200447A1 Oxazinocarbazoles for the treatment of cns diseases |
| 05/02/2002 | EP1200446A1 OXATHIEPINO 6,5- i b /i ]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 05/02/2002 | EP1200445A1 Thienopyranecarboxamide derivatives |
| 05/02/2002 | EP1200435A1 Purine derivatives inhibitors of tyrosine protein kinase syk |
| 05/02/2002 | EP1200422A2 Pyrazole compositions useful as inhibitors of erk |
| 05/02/2002 | EP1200419A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 05/02/2002 | EP1200406A1 Cyclic amides and imides having selective antagonist activity at alpha-1d adrenergic receptor |
| 05/02/2002 | EP1200402A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 05/02/2002 | EP1200400A1 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
| 05/02/2002 | EP1200398A1 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors |
| 05/02/2002 | EP1200137A1 Agent for occluding blood vessels |
| 05/02/2002 | EP1200118A1 A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug |
| 05/02/2002 | EP1200117A2 Lipoprotein lipase (lpl) variant therapeutics |
| 05/02/2002 | EP1200116A2 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
| 05/02/2002 | EP1200114A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 05/02/2002 | EP1200095A1 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 05/02/2002 | EP1200085A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 05/02/2002 | EP1200084A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 05/02/2002 | EP1200082A1 Preparations for reducing oxygen consumption during physical efforts |
| 05/02/2002 | EP1146875A4 Myt1 kinase inhibitors |
| 05/02/2002 | EP1021189B1 Desferri-exochelin for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation |
| 05/02/2002 | EP0931086B1 Tetrahydronaphthalene derivatives and their therapeutic use |
| 05/02/2002 | EP0885004B1 Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers |
| 05/02/2002 | EP0841907B1 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity |
| 05/02/2002 | EP0840740B1 New inhibitors of platelet aggregation |
| 05/02/2002 | DE10052658A1 Neue Pyranosidderivate New Pyranosidderivate |
| 05/02/2002 | DE10052333A1 Neue Sulfooxybenzamide New Sulfooxybenzamide |
| 05/02/2002 | DE10049549A1 Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40 |
| 05/02/2002 | CA2689012A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2678256A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2427085A1 Transmembrane proteins |
| 05/02/2002 | CA2427024A1 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | CA2427005A1 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | CA2426773A1 Beta-substituted beta-aminoethyl phosphonates |
| 05/02/2002 | CA2426736A1 Vegf peptides and their use for inhibiting angiogenesis |
| 05/02/2002 | CA2426674A1 Agent for preventing or treating portal hypertension |
| 05/02/2002 | CA2426672A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 05/02/2002 | CA2426564A1 Pyranoside derivatives |
| 05/02/2002 | CA2426244A1 Lipid formulations for target delivery |
| 05/02/2002 | CA2426007A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 05/02/2002 | CA2425288A1 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | CA2425283A1 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2425280A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2424475A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2422787A1 C-nitroso compounds and use thereof |
| 05/02/2002 | CA2421885A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2420164A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/01/2002 | CN1347414A Triazole compounds with dopamine-D3-receptor affinity |
| 05/01/2002 | CN1347411A Sulfonamide derivs. having oxadiazole rings |
| 05/01/2002 | CN1347408A Use of maduraphthalazine derivs. as inhibitors of pro-inflammatory cytokins |
| 05/01/2002 | CN1347398A Salts of asiatic and madecassic acid suitable for preparation of pharmaceutical and cosmetic compositions |
| 05/01/2002 | CN1347326A BAFF, inhibitors thereof and their use in modulation of B-cell response |
| 05/01/2002 | CN1347321A Use of vasopeptidase inhibitors to treat angina pectoris |
| 05/01/2002 | CN1347320A Use of cholesterol-lowering agent |
| 05/01/2002 | CN1347318A Inhibitors of IMPDH enzyme |
| 05/01/2002 | CN1347283A eNOS mutations useful for gene therapy and therapeutic screening |
| 05/01/2002 | CN1346830A Novel 2,4-dioxopyrrolidone and 2,4-dioxotetrahydro-furan derivs. and medicine contg. them as active component |
| 05/01/2002 | CN1346828A Dicyclic aromatic compound and use thereof in human or animal medicine and cosmetic process |
| 05/01/2002 | CN1346650A Antihypertensive pueraria root liquid and its preparing process |
| 05/01/2002 | CN1346648A Diemailing injection and its preparing process |